Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...
Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential
David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback